Swiss National Bank Grows Holdings in Eli Lilly and Co (LLY)
Swiss National Bank raised its stake in Eli Lilly and Co (NYSE:LLY) by 0.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 4,173,743 shares of the company’s stock after acquiring an additional 16,300 shares during the quarter. Swiss National Bank’s holdings in Eli Lilly and were worth $352,514,000 as of its most recent SEC filing.
A number of other large investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Eli Lilly and by 2.3% during the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock valued at $5,778,109,000 after acquiring an additional 1,610,885 shares in the last quarter. BlackRock Inc. grew its stake in shares of Eli Lilly and by 2.1% during the second quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock valued at $5,232,942,000 after acquiring an additional 1,323,259 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Eli Lilly and by 16.1% during the third quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock valued at $928,719,000 after acquiring an additional 1,503,918 shares in the last quarter. Dodge & Cox grew its stake in shares of Eli Lilly and by 22,094.9% during the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock valued at $493,138,000 after acquiring an additional 5,964,955 shares in the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Eli Lilly and by 91.1% during the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock valued at $468,691,000 after acquiring an additional 2,714,505 shares in the last quarter. 76.45% of the stock is currently owned by institutional investors.
Eli Lilly and Co (NYSE LLY) opened at $76.23 on Friday. The company has a market capitalization of $81,712.27, a PE ratio of -381.13, a P/E/G ratio of 1.36 and a beta of 0.23. Eli Lilly and Co has a 52 week low of $73.69 and a 52 week high of $89.09. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 0.66.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be issued a $0.5625 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a yield of 2.95%. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio (DPR) is currently -1,039.95%.
In other Eli Lilly and news, SVP Jeffrey N. Simmons sold 9,625 shares of the firm’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $81.12, for a total value of $780,780.00. Following the transaction, the senior vice president now owns 152,120 shares of the company’s stock, valued at $12,339,974.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the transaction, the insider now directly owns 4,130 shares in the company, valued at approximately $334,901.70. The disclosure for this sale can be found here. Insiders sold 259,610 shares of company stock worth $22,727,406 in the last three months. 0.20% of the stock is currently owned by corporate insiders.
Several analysts have recently weighed in on the company. Bank of America lowered their target price on Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday, February 1st. Credit Suisse Group restated a “hold” rating and set a $80.00 target price on shares of Eli Lilly and in a research note on Friday, February 2nd. BMO Capital Markets raised their target price on Eli Lilly and from $73.00 to $74.00 and gave the company an “underperform” rating in a research note on Thursday, February 1st. Piper Jaffray Companies reiterated a “buy” rating and issued a $105.00 price target on shares of Eli Lilly and in a research note on Friday, October 13th. Finally, Goldman Sachs Group downgraded Eli Lilly and from a “buy” rating to a “neutral” rating and lifted their price target for the stock from $86.98 to $95.00 in a research note on Tuesday, January 16th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. Eli Lilly and has a consensus rating of “Hold” and a consensus price target of $92.02.
ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.dailypolitical.com/2018/02/10/swiss-national-bank-grows-holdings-in-eli-lilly-and-co-lly.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.